Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:687
Name hepatoblastoma
Definition
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer gastrointestinal system cancer hepatobiliary system cancer liver cancer hepatoblastoma

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT00980460 Phase III Irinotecan + Temsirolimus + Vincristine Sulfate Cisplatin + Fluorouracil + Vincristine Sulfate Doxorubicin Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer Active, not recruiting USA | CAN | AUS 3
NCT01331135 Phase I Sirolimus Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors Completed USA 0
NCT01956669 Phase II Pazopanib Pazopanib Paediatric Phase II Trial Children's Oncology Group (COG) in Solid Tumors Completed USA | FRA | ESP | CAN 3
NCT02867592 Phase II Cabozantinib Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Active, not recruiting USA 0
NCT03017326 Phase III Cisplatin Carboplatin + Etoposide Gemcitabine + Oxaliplatin + Sorafenib Cisplatin + Doxorubicin + Sorafenib Cisplatin + Doxorubicin + Gemcitabine + Oxaliplatin + Sorafenib Carboplatin + Doxorubicin Irinotecan + Vincristine Sulfate Cisplatin + Doxorubicin + Fluorouracil + Vincristine Sulfate Cisplatin + Doxorubicin Carboplatin + Cisplatin + Doxorubicin Paediatric Hepatic International Tumour Trial (PHITT) Recruiting NLD | GBR | FRA | ESP | DEU | BEL | AUT 6
NCT03155620 Phase II Tazemetostat Larotrectinib LY3023414 Vemurafenib Palbociclib Olaparib Ulixertinib Erdafitinib Selumetinib Ensartinib Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial) Recruiting USA | CAN | AUS 1
NCT03210714 Phase II Erdafitinib Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03213678 Phase II LY3023414 Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03213704 Phase II Larotrectinib Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03233204 Phase II Olaparib Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT03533582 Phase II Cisplatin + Doxorubicin + Gemcitabine + Oxaliplatin + Sorafenib Cisplatin + Doxorubicin + Fluorouracil + Vincristine Sulfate Carboplatin + Cisplatin + Doxorubicin + Etoposide Carboplatin + Cisplatin + Doxorubicin + Irinotecan + Vincristine Sulfate Cisplatin Cisplatin + Doxorubicin + Sorafenib Cisplatin + Doxorubicin Carboplatin + Cisplatin + Doxorubicin Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery Active, not recruiting USA | NZL | CAN | AUS 2
NCT03654716 Phase I ALRN-6924 + Cytarabine ALRN-6924 Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer Completed USA 0
NCT03698994 Phase II Ulixertinib Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial) Active, not recruiting USA 1
NCT04634357 Phase Ib/II ET140203 ET140203 T-Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma (ARYA-2) Recruiting USA 0
NCT04851119 Phase Ib/II BC2059 Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors Recruiting USA 0
NCT04928677 Phase I Codrituzumab A Study of Codrituzumab in Children and Young Adults With Solid Tumors and Have Not Responded to Treatment or Have Come Back After Treatment Recruiting USA 0
NCT05064306 Expanded access Omburtamab I-131 131I-omburtamab for the Treatment of Central Nervous System/Leptomeningeal Neoplasms in Children and Young Adults Available USA 0